Teva Pharmaceutical Industries has launched a generic version of Elidel (pimecrolimus) Cream, 1% in the US, a topical prescription medicine indicated for use as a second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis).
Elidel (pimecrolimus) Cream, 1% has approval to be used for the treatment of non-immunocompromised adults and children two years of age and older who did not adequately respond to other topical prescription treatments, or when those treatments are not recommended.
Brendan O’Grady – EVP and Head of North America Commercial at Teva Pharmaceutical said: “We’re proud to offer another affordable treatment option. This launch represents an important addition to our generics portfolio and underscores our commitment to ensuring that patients have more treatment options.”
As per IQVIA data as of October 2018, Elidel Cream, 1% had registered annual sales of around $218.4 million in the US.